Insiders Verve Therapeutics, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 15:32:27 10/05/2024 BST			5-day change	1st Jan Change
6.115 ^USD	-3.85%		-3.14%	-55.46%

05-07	Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102	CI
04-03	Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating	MT

Verve Therapeutics Appoints Frederick Fiedorek as Chief Medical Officer	18/09/23	MT
Verve Therapeutics, Inc. Announces Executive Changes	18/09/23	CI
Insider Sell: Verve Therapeutics	09/11/22	MT
Insider Sell: Verve Therapeutics	04/11/22	MT
Insider Sell: Verve Therapeutics	03/11/22	MT
Insider Sell: Verve Therapeutics	01/11/22	MT
Insider Sell: Verve Therapeutics	05/10/22	MT
Insider Sell: Verve Therapeutics	27/09/22	MT
ESC 2022 Investor Presentation: Nomination of VERVE-201 ANGPTL3 Product Candidate	22/08/22	PU
Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress	22/08/22	GL
Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress	22/08/22	AQ
Insider Sell: Verve Therapeutics	11/08/22	MT
Verve Therapeutics, Inc. Announces Board and Committee Changes	09/08/22	CI
ESC 2022 Poster: Nomination of VERVE-201 ANGPTL3 Product Candidate	31/07/22	PU
Insider Sell: Verve Therapeutics	22/07/22	MT
Insider Sell: Verve Therapeutics	21/07/22	MT
Insider Sell: Verve Therapeutics	15/07/22	MT
Verve Therapeutics Appoints Alexander G. "Bo" Cumbo, to Its Board of Directors	13/06/22	CI
Insider Sell: Verve Therapeutics	29/12/21	MT
Insider Sell: Verve Therapeutics	28/12/21	MT

No results for this search